Summary

Eligibility
for people ages 21-100 (full criteria)
Location
at UC Davis UC Irvine
Dates
study started
completion around
Principal Investigator
by Marian Waterman (uci)

Description

Summary

This trial establishes patient-derived cancer xenografts in addressing cancer health and treatment disparities that disproportionately affect racial/ethnic minorities. Understanding the genetic and response differences among racial/ethnic minorities may help researchers enhance the precision of therapeutic treatments.

Official Title

University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities

Details

Keywords

Bladder Carcinoma, Gastric Carcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Lung Carcinoma, Malignant Neoplasm, Carcinoma, Neoplasms, Stomach Neoplasms, Urinary Bladder Neoplasms, Ductal Carcinoma, Biospecimen Collection, Ancillary-correlative (biospecimen collection)

Eligibility

Locations

  • UC Irvine Health/Chao Family Comprehensive Cancer Center accepting new patients
    Orange California 92868 United States
  • University of California Davis Comprehensive Cancer Center accepting new patients
    Sacramento California 95817 United States

Lead Scientist at University of California Health

  • Marian Waterman (uci)
    Recall Hcomp, Microbiology and Molecular Genetics, School of Medicine. Authored (or co-authored) 71 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, Davis
ID
NCT04410302
Study Type
Observational
Participants
Expecting 500 study participants
Last Updated